title: Long-term BCR-ABL1 Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia.
abstract: With the success of tyrosine kinase inhibitor (TKI) therapy for the treatment of patients with chronic myeloid leukemia (CML), CML is now treated as a chronic disease. As such, the community of oncologists may see patients with CML more often than the primary-care physician and must focus on long-term management of adverse events and adherence. BCR-ABL1 TKIs are effective therapies in CML but are associated with distinct safety profiles. Thus, selection of long-term treatment with any TKI requires assessment of patient comorbidities and regular monitoring to identify the potential emergence of adverse effects or new risk factors. With a focus on long-term safety, this review provides a holistic picture of the primary care needs of patients with CML, emphasizing on the importance of community oncologists who in many cases act as both oncologists and primary-care physicians.
authors.affiliation: H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, U.S.A. Javier.Pinilla@moffitt.org.
authors.forename: Javier
authors.initials: J
authors.lastname: Pinilla-Ibarz
authors.affiliation: H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, U.S.A.
authors.forename: Kendra
authors.initials: K
authors.lastname: Sweet
authors.affiliation: H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, U.S.A.
authors.forename: Josephine
authors.initials: J
authors.lastname: Emole
authors.affiliation: H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, U.S.A. University of South Florida Division of Cardiovascular Medicine, Tampa, FL, U.S.A.
authors.forename: Michael
authors.initials: M
authors.lastname: Fradley
mesh_terms: D016044:Fusion Proteins, bcr-abl / Q000378:metabolism*; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D047428:Protein Kinase Inhibitors; D016044:Fusion Proteins, bcr-abl
keywords: BCR-ABL1; adherence; adverse effects; chronic myeloid leukemia; medication; review; therapy management